🔴 Femasys is trading 6% down on October 15 with no clear company-specific catalyst

Femasys is trading at $1.47, down 5.96%, with no clear company-specific catalyst identified for the October 15 decline.

• The October 14 announcement that FemBloc trial sites had doubled to twelve was positive, not an explanation for the drop.
• Broader risk-off sentiment was a plausible factor as hotter-than-expected inflation and technology-stock selling pressured markets; the Nasdaq fell 1.16%.
• The update reported pre-market trading at $1.48, down 5.13%, and no clear company-specific news.